HYPERSENSITIVITY REACTIONS FROM TAXOL
HYPERSENSITIVITY REACTIONS FROM TAXOL
复制标题
DOI：
10.1200/jco.1990.8.7.1263
复制
发表时间：
1990-07-01
影响因子：
45.3
通讯作者：
LEYLANDJONES, B
中科院分区：
文献类型：
--
作者：
WEISS, RB;DONEHOWER, RC;LEYLANDJONES, B
紫杉醇是一种抗肿瘤药物，在临床试验中已被证明对晚期卵巢癌和黑色素瘤具有活性。超敏反应（HSR）是使用该药物观察到的毒性之一。在接受治疗的301例患者中，32例患者对紫杉醇有明确的（27例）或可能的（5例）超敏反应。除一名患者外，所有患者均在第一次或第二次暴露于该药剂时发生反应。反应发生在各种剂量下，最常见的特征为呼吸困难、低血压、支气管痉挛、荨麻疹和皮疹。13例（41%）患者接受了旨在预防此类毒性的术前用药;然而，他们持续发生了HSR。延长药物输注似乎在一定程度上降低了但不能消除HSR的风险。这些与紫杉醇反应的原因（紫杉醇本身或其赋形剂Cremophor EL; Badische Anilin und Soda-Fabrik AG [BASF]，Ludwigshafen，联邦共和国德国）和机制尚不清楚。我们提供指导方针，以防止或尽量减少这种毒性和治疗反应，如果他们仍然发生。
Taxol is an antitumor agent in clinical trial that has been shown to have activity against advanced ovarian carcinoma and melanoma. Hypersensitivity reactions (HSRs) have been one of the toxicities observed with administration of this drug. Of 301 patients treated, 32 patients have had definite (27 patients) or possible (five patients) hypersensitivity reactions to taxol. All but one patient had the reaction from the first or second exposure to this agent. Reactions occurred at a variety of doses and were characterized most frequently by dyspnea, hypotension, bronchospasm, urticaria, and erythematous rashes. Thirteen (41%) patients had received premedication designed to prevent such toxicity; nevertheless, they sustained HSRs. Prolonging the drug infusion appears to have somewhat reduced, but not obviated, the risk of HSRs. The cause (taxol itself or its excipient Cremophor EL; Badische Anilin und Soda-Fabrik AG [BASF], Ludwigshafen, Federal Republic of Germany) and the mechanism of these reactions to taxol are unknown. We provide guidelines to prevent or minimize such toxicity and treat reactions if they still occur.